Your browser doesn't support javascript.
loading
CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia.
D'Arena, Giovanni; Vitale, Candida; Coscia, Marta; Lamorte, Daniela; Pietrantuono, Giuseppe; Perutelli, Francesca; D'Auria, Fiorella; Statuto, Teodora; Valvano, Luciana; Tomasso, Annamaria; Griggio, Valentina; Jones, Rebecca; Mansueto, Giovanna; Villani, Oreste; D'Agostino, Simona; Viglioglia, Vito; De Feo, Vincenzo; Calapai, Fabrizio; Mannucci, Carmen; Sgambato, Alessandro; Efremov, Dimitar G; Laurenti, Luca.
Afiliación
  • D'Arena G; Hematology, P.O.S. Luca ASL Salerno, 84078 Vallo della Lucania, Italy.
  • Vitale C; Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
  • Coscia M; Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
  • Lamorte D; Laboratory of Pre-Clinical and Translational Research, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Pietrantuono G; Hematology and Stem Cell Transplantation Unit, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Perutelli F; Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
  • D'Auria F; Laboratory of Clinical and Advanced Diagnostics, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Statuto T; Laboratory of Clinical and Advanced Diagnostics, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Valvano L; Laboratory of Clinical and Advanced Diagnostics, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Tomasso A; Hematology Unit, Fondazione Policlinico Gemelli, IRCCS, Catholic University of Sacred Hearth, 00168 Rome, Italy.
  • Griggio V; Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
  • Jones R; Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
  • Mansueto G; Hematology and Stem Cell Transplantation Unit, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Villani O; Hematology and Stem Cell Transplantation Unit, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • D'Agostino S; Hematology and Stem Cell Transplantation Unit, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Viglioglia V; Scientific Direction, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • De Feo V; Department of Pharmacy, University of Salerno, 84084 Salerno, Italy.
  • Calapai F; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98124 Messina, Italy.
  • Mannucci C; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98124 Messina, Italy.
  • Sgambato A; Scientific Direction, Centro di Riferimento Oncologico della Basilicata (IRCCS CROB), 71013 Rionero in Vulture, Italy.
  • Efremov DG; Molecular Hematology, International Center for Genetic Engineering and Biotechnology, 341949 Trieste, Italy.
  • Laurenti L; Hematology Unit, Fondazione Policlinico Gemelli, IRCCS, Catholic University of Sacred Hearth, 00168 Rome, Italy.
Cancers (Basel) ; 13(16)2021 Aug 23.
Article en En | MEDLINE | ID: mdl-34439393
Membrane-bound CD200 is overexpressed in chronic lymphocytic leukemia (CLL), and there is some evidence that its soluble ectodomain (sCD200) could also be involved in the pathophysiology and the disease. However, very little is known about sCD200's prognostic significance. sCD200 was tested at diagnosis in 272 patients with CLL and in 78 age- and sex-matched healthy subjects using a specific human CD200 (OX-2 membrane glycoprotein) ELISA kit. A significantly higher concentration of sCD200 was found in CLL patients compared to controls. In our cohort, sCD200 was significantly higher in patients who were older than 66 years, with Binet stage C, unmutated IgVH and unfavorable (del11q or del17p) FISH. Time-to-first treatment and overall survival were significantly shorter in patients with higher sCD200 concentration, using as a cut-off 1281 pg/mL, the median value for sCD200 concentration in the whole CLL cohort. However, the prognostic impact of sCD200 was not confirmed in multivariate analysis. Baseline sCD200 values appeared to have an impact on the response to chemotherapy or chemo-immunotherapy, but not to targeted agents. Collectively, our data show that sCD200 serum levels correlate with more aggressive clinical and biological features and are able to predict a worse prognosis. This work supports the relevant role of CD200 not only as a diagnostic tool but also as a prognostic indicator and a potential therapeutic target in CLL.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza